Release Date: 18-Jul-2024
Envafolimab is a pioneering single domain anti-PD-L1 antibody developed by Alphamab Oncology. In November 2021, it received approval from China’s NMPA for treating adult patients with MSI-H or dMMR advanced solid tumors, as well as other advanced solid tumors with limited treatment options. This breakthrough therapy also earned the US FDA’s orphan drug designation for advanced biliary tract cancer.
A pivotal phase II clinical study demonstrated Envafolimab’s efficacy and safety in patients with advanced dMMR/MSI-H tumors, showing good tolerability with no reported cases of several common immune-related adverse events. Notably, Envafolimab is the first subcutaneously administered PD-L1 antibody, offering significant advantages over traditional intravenous infusions. This innovation allows for rapid 30-second administration in a physician’s office, enhancing convenience, reducing treatment time, and minimizing the risk of infusion reactions, marking a significant advancement in cancer immunotherapy.
For More Information on Drug Trials in China Contact